- Home
- PAVM vs ONCO Comparison
PAVM vs ONCO Comparison
Compare PAVM & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | ONCO |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 4.3M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PAVM | ONCO |
|---|---|---|
| Price | $9.04 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $510.00 | N/A |
| AVG Volume (30 Days) | 27.6K | ★ 57.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $29,000.00 | ★ $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $1.37 |
| 52 Week High | $26.85 | $88.40 |
Technical Indicators
Market Signals| Indicator | PAVM | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 91.63 | 39.87 |
| Support Level | $6.26 | $1.48 |
| Resistance Level | $9.28 | $1.61 |
| Average True Range (ATR) | 0.78 | 0.14 |
| MACD | 0.54 | 0.04 |
| Stochastic Oscillator | 97.35 | 45.10 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.